Search | Clinical Trials Finder

Conditions: Healthy
Interventions: MVA-BN-Filo, Ad26. ZEBOV, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: COVID-19
Interventions: AZD3152, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 54
States / cities: Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 46 more

Conditions: Phase 1 First-in-human Study Involving Healthy Subjects
Interventions: TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH); Drug · Biological
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Clostridoides Difficile Associated Disease
Interventions: C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 936 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 23
States / cities: Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more

Conditions: Post-operative Surgical Pain
Interventions: Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions: Bacillus Calmette-Guérin, Saline Injection; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 9 more

Conditions: Alzheimer's Disease
Interventions: Sagramostim, Saline -- placebo comparator; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pain
Interventions: Saline Solution for Injection, Exparel; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Osteoarthritis, Knee
Interventions: Pentosan Polysulfate Sodium twice weekly, Placebo; Drug
Lead sponsor: Paradigm Biopharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 41
States / cities: Peoria, Arizona • Tucson, Arizona • Anaheim, California + 34 more

Conditions: Type 1 Diabetes
Interventions: Muscle Biopsy, Jell-O with Amino acids, Dextrose; Procedure · Other · Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Urinary Incontinence, Urinary Bladder, Overactive
Interventions: BOTOX®; Biological
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 8
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more

Conditions: HIV Infections
Interventions: AVX101, placebo; Biological · Other
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 6
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York + 2 more

Conditions: Vascular Inflammation, ASCVD, ASCVD Management
Interventions: CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus, Healthy
Interventions: JNJ-55920839, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina

Conditions: Post Operative Pain
Interventions: 0.25% bupivicaine will be injected at the study port site prior to incision, Saline will be injected at the study port site prior to incision, Saline will be in injected into the port site prior to closure, 0.25% bupivicaine will be injected into the port site prior to closure; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Chronic Patellar Tendinopathy, Chronic PT
Interventions: platelet rich plasma, saline; Biological · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions: OnabotulinumtoxinA 100 UNT; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Tampa, Florida

Conditions: Pedal Fat Pad Atrophy
Interventions: Pedal Fat Grafting, Local anesthetic; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Myeloid Leukaemia (AML)
Interventions: Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.; Drug
Lead sponsor: Moleculin Biotech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more

Conditions: Type 1 Diabetes
Interventions: Insulin Degludec, Insulin Glargine, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis, Post-traumatic; Arthrosis
Interventions: methylprednisolone acetate, active comparator; Drug
Lead sponsor: New Lexington Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Generalized Anxiety Disorder
Interventions: RE104 for Injection, Placebo; Drug
Lead sponsor: Reunion Neuroscience Inc; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more

Search by objective public record fields.

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

EXPAREL for Minimally Invasive Supracervical Hysterectomies

A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy

Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

Fat Grafting for Pedal Fat Pad Atrophy

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder